Antibodies to sICAM-1
US5821341A · kind A · utility
11Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 1995 |
| Grant date | Oct 13, 1998 |
| Priority date | — |
| Expiry date | May 18, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a soluble form of intercellular adhesion molecule (sICAM-1) and purified and isolated human sICAM-1, and antibodies thereto. This invention also relates to a purified and isolated DNA sequence encoding sICAM-1. The extracellular domain of sICAM-1 and insoluble ICAM-1 are substantially the same. ICAM-1 is involved in the process through which lymphocytes attach to cellular substrates during inflammation and serves as the major human rhinovirus receptor (HRR). sICAM-1 therefore has both the property of reducing immune inflammation and inhibiting infection of rhinovirus and Coxsackie A virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.